Ergothioneine for Eye Health: Research and Implications

Ergothioneine & Eye Health

#1 antioxidant for RPE cell protection

In a 2024 antioxidant screen for retinal pigment epithelium protection, L-ergothioneine was identified as the lead cytoprotective compound, acting through NRF2 activation.

Gu et al., Exp Eye Res, 2024

14% lower mortality

per SD-higher plasma ergothioneine across 3,236 participants (Smith 2020)

OCTN1 in ocular tissue

the dedicated ergothioneine transporter is highly expressed in eye tissues under oxidative stress (Wijesinghe 2023)

Depleted with age

whole-blood ergothioneine falls after age 60 and is lower in mild cognitive impairment (Cheah 2016)

Gu et al., Exp Eye Res, 2024

View as image ↗

The story of ergothioneine eye health changed in 2024 when a research team at a Chinese ophthalmology institute ran a systematic screen. They took retinal pigment epithelium cells, the layer of cells behind the retina that supports photoreceptors and whose death drives age-related macular degeneration, and exposed them to oxidative stress. Then they tested dozens of antioxidants for protective effect. L-ergothioneine came out first.^[1]

It emerged from the screen as the lead cytoprotective compound. It activated the NRF2 antioxidant pathway, maintained the redox balance and normal function of the RPE cells, and preserved normal retinal structure in a mouse oxidative stress model.

No competitor article has covered this finding. It was published in Experimental Eye Research, a dedicated ophthalmology journal, and it establishes ergothioneine eye health as a serious research topic, not a wellness trend.

For the foundational biology of what ergothioneine is and how its dedicated transporter works, see what ergothioneine is and why the body hoards it. This article covers the full eye health evidence: both what the 2023-2024 research shows and what it honestly doesn't.

What Ergothioneine Does for Eye Health: The Short Answer

Ergothioneine is a dietary antioxidant found almost exclusively in mushrooms that concentrates in eye tissues, especially the lens and the retina, via OCTN1, its dedicated import transporter. It quenches singlet oxygen, chelates metal ions that generate damaging radicals, and activates the NRF2 antioxidant pathway, targeting the three main mechanisms behind UV-driven oxidative damage in both tissues.

This short answer covers the mechanism. The rest of this article covers the research behind each part of it.

The Gu 2024 Finding: Ergothioneine Tops the RPE Antioxidant Screen

The most directly relevant study in the current ergothioneine eye health literature is Gu and colleagues' 2024 paper in Experimental Eye Research.^[1]

The study was designed to identify the best antioxidant for protecting retinal pigment epithelium (RPE) cells. RPE cells form the layer immediately behind the photoreceptors. They provide nutrients to photoreceptors, clear waste products, and absorb stray UV light. Their degeneration is the central pathological event in age-related macular degeneration (AMD). Finding antioxidants that protect RPE cells is directly relevant to AMD prevention and treatment.

Gu's team screened a library of antioxidant candidates under oxidative stress conditions modeling what RPE cells experience in AMD. L-ergothioneine emerged as the lead cytoprotective compound. It activated the NRF2 pathway, a master switch for antioxidant gene expression that protects cells from oxidative damage; when the researchers blocked NRF2, ergothioneine's protective effect disappeared, pinning NRF2 activation as central to its mechanism. In a mouse model of oxidative stress, ergothioneine-treated animals maintained normal retinal structure.

The study doesn't prove ergothioneine supplementation prevents AMD in humans. It is preclinical. But it is the kind of study that identifies where clinical research should be directed, and it is published in a peer-reviewed ophthalmology journal that specifically evaluates eye disease therapeutics.

Before the Eye Research: Why Ergothioneine Has Scientific Credibility

The eye-specific evidence sits within a broader research context that gives it more weight.

In 2020, Smith and colleagues published a landmark cohort analysis in the journal Heart using data from 3,236 participants in the Malmö Diet and Cancer Study, followed for a median of 21.4 years.^[2] Each standard-deviation increase in plasma ergothioneine was associated with 14% lower all-cause mortality (hazard ratio 0.86) and 21% lower cardiovascular mortality (hazard ratio 0.79). Of all the plasma metabolites measured, ergothioneine was the single one most strongly connected to a health-conscious dietary pattern.

This is the largest human population study connecting ergothioneine levels to health outcomes. It cannot establish causation, as lower ergothioneine might be a marker of poor diet rather than a driver of worse outcomes, but the effect size is substantial and the sample size is well-powered. It demonstrates that plasma ergothioneine is not an inert measurement.

The population data puts the eye-specific findings in context. If low ergothioneine is associated with worse systemic health outcomes, it would be surprising if tissues that depend heavily on ergothioneine's specific protective functions (the lens and retina, which express dedicated OCTN1 importers) were unaffected by those lower levels.

Why the Body Built a Dedicated Transport System for These Tissues

The most fundamental question about ergothioneine and eye health is why the lens and retina accumulate it at all. The answer involves a transporter protein and an evolutionary argument.

In 2005, Gründemann and colleagues identified OCTN1 (SLC22A4) as the specific, dedicated transporter for ergothioneine.^[3] This transporter actively concentrates ergothioneine in cells, against the concentration gradient, using cellular energy. It is not a general antioxidant transporter; it handles ergothioneine with far greater affinity than any other substrate.

Gründemann's 2022 review of the transporter established a crucial constraint: because the cell membrane is essentially impermeable to ergothioneine, only cells that display OCTN1 on their surface can take it up and concentrate it.^[4] Where ergothioneine accumulates therefore maps directly onto where the transporter is expressed. And OCTN1 is strongly expressed in ocular tissues predisposed to oxidative stress, as documented in Wijesinghe and colleagues' retinal work.^[9] The eye tissues under the heaviest oxidative load carry their own dedicated ergothioneine import system.

In 2018, Bruce Ames at UC Berkeley proposed that any compound for which the human body evolved a dedicated transporter should be considered biologically essential, meaning deficiency leads to insidious long-term damage in exactly the tissues where the transporter is expressed.^[5] Applied to the eye: the lens and retina both depend on OCTN1 for ergothioneine supply. If dietary intake drops, both tissues are exposed to higher chronic oxidative stress with less defense. The Ames framework suggests this matters, because the body built the infrastructure specifically to prevent it.

For a deep dive on OCTN1 in retinal tissue specifically, see OCTN1 in the Retina: Ergothioneine and Macular Degeneration.

How Ergothioneine Protects the Lens: What the Cataract Evidence Shows

The lens evidence predates the retinal evidence by four decades. In 1981, Shukla and colleagues analyzed ergothioneine content in lens tissue from cataract patients and from age-matched controls with normal vision.^[6] Cataractous lenses had markedly lower ergothioneine. This remains the only direct human tissue analysis connecting ergothioneine depletion to clinical lens disease.

The mechanism involves the specific threat the lens faces. UV light generates singlet oxygen in lens tissue continuously. Ergothioneine is an unusually effective singlet oxygen quencher, as characterized in detail in Cheah and Halliwell's authoritative 2021 review of ergothioneine biology.^[7] Most common antioxidants are not good singlet oxygen quenchers. Ergothioneine is, which gives it a specific advantage in the UV-exposed lens environment.

A second mechanism operates alongside the direct quenching. In a 2024 UV-exposure study, Li and colleagues showed ergothioneine activates the PI3K/AKT/Nrf2 pathway under ultraviolet oxidative stress, switching on the cell's own antioxidant gene expression response.^[8] That work was carried out in skin rather than eye tissue, so it is a mechanistic analogy, not direct lens evidence, but the same Nrf2 pathway operates in lens epithelial cells. The plausible picture in the lens is thus both direct protection (quenching the reactive species) and indirect protection (activating the cellular antioxidant response to keep quenching capacity high).

For the full cataract-specific evidence, see Ergothioneine and Cataract Prevention.

How Ergothioneine Protects the Retina: The 2023-2024 Research

The retinal evidence is newer and comes in three distinct threads, each addressing a different mechanism behind AMD.

NRF2 activation in RPE cells. Gu 2024's screening finding, discussed above, establishes ergothioneine as a leading antioxidant candidate for RPE protection via NRF2 activation.^[1] NRF2's role in defending against AMD is well-established in the ophthalmology literature; identifying ergothioneine as the compound that engaged it from a full antioxidant screen is a meaningful result.

Amyloid beta clearance in the neuroretina. In 2023, Wijesinghe and colleagues studied ergothioneine supplementation in Alzheimer's model mice and found something relevant to AMD: ergothioneine reduced amyloid beta accumulation in the neuroretina.^[9] The neuroretina is the part of the retina containing the photoreceptors and their support cells. Amyloid beta deposits in the retina are also found in AMD; the same pathological protein implicated in Alzheimer's dementia appears in macular tissue. Wijesinghe 2023 establishes ergothioneine's capacity to clear this deposit in a neuroretinal context, providing a mechanistic bridge between ergothioneine, Alzheimer's pathology in the retina, and AMD.

Cellular senescence. A 2024 study by Apparoo and colleagues used an ergothioneine-rich shiitake mushroom extract in a neuronal cell model and found it reduced cellular senescence.^[10] Cellular senescence, the state where cells stop dividing and begin secreting inflammatory signals, is a recognized driver of AMD pathology in the RPE: senescent RPE cells accelerate the degeneration of surrounding photoreceptors. The Apparoo work was done in neuronal cells rather than RPE, but the retina is neural tissue, and a compound that clears senescent cells in a neural model speaks to one of the upstream mechanisms behind AMD.

These three threads (NRF2 activation, amyloid clearance, and senescence elimination) represent mechanistically distinct pathways, all converging on protection of the tissues damaged in AMD. No competitor has synthesized all three. For the full AMD-specific evidence synthesis, see Ergothioneine and Macular Degeneration: Retinal Protection Research.

Age-Related Depletion: Why Eye Risk Rises as Ergothioneine Falls

One thread that runs through the research is temporal: ergothioneine levels in humans decline with age, and the eye diseases connected to ergothioneine, cataracts and AMD, are themselves age-related conditions. The timing is not coincidental.

In 2016, Cheah and colleagues measured ergothioneine levels in older adults and found that whole-blood ergothioneine declines significantly beyond age 60, and that a subset of subjects with mild cognitive impairment had significantly lower plasma ergothioneine than age-matched controls.^[11] The cognitive impairment finding is relevant to eye health because the retina is an extension of the central nervous system; it is brain tissue, and conditions that deplete ergothioneine systemically expose it too.

The relevance of age-related depletion was reinforced at the animal level in 2024, when Katsube and colleagues, writing in GeroScience, showed that daily oral ergothioneine (about 4–5 mg/kg/day) extended lifespan and reduced frailty and cognitive decline in male mice.^[12] This is a direct animal longevity study for ergothioneine, and it supports the Ames "longevity vitamin" framing: as ergothioneine depletes with age, the tissues that depend on it lose antioxidant defense.

The implication for eye health: the tissues most dependent on ergothioneine (lens and retina, both high-OCTN1-expressing) face increasing oxidative stress at the same time that dietary and plasma ergothioneine decline. AMD and cataracts peak at ages when ergothioneine levels are lowest.

This doesn't prove that replenishing ergothioneine reverses or prevents those conditions. It does suggest the timeline of depletion and the timeline of disease are connected in ways worth investigating clinically.

The Evidence Ceiling: What This Research Does and Doesn't Establish

The mechanistic case for ergothioneine and eye health is the strongest it has ever been. The recent wave of studies adds mechanism data at several levels: the direct RPE screen in an ophthalmology journal (Gu 2024), amyloid-clearance work in the neuroretina (Wijesinghe 2023), and antisenescence and UV-pathway findings drawn from neuronal and skin models (Apparoo 2024; Li 2024). The transporter biology establishes why the lens and retina accumulate ergothioneine at all. The population data from Smith 2020 establishes that plasma ergothioneine levels correlate meaningfully with health outcomes.

What this evidence does not yet provide: any human randomized controlled trial testing ergothioneine supplementation for cataracts, AMD, or any eye condition. Every mechanistic finding is from cell cultures or animal models. The Shukla 1981 tissue data is observational. The Smith 2020 population data is associational.

The honest position: the biological case is well-developed and the preclinical evidence is genuinely encouraging, particularly the Gu 2024 RPE finding. Human clinical trials are the missing step. Those trials haven't been run yet for any eye indication.

Getting Ergothioneine Through Diet: Mushrooms as the Practical Source

Ergothioneine is synthesized almost exclusively by fungi. For humans, mushrooms are the practical dietary source.

Content varies substantially by species. Porcini mushrooms (also called ceps) are among the highest-ergothioneine sources. Oyster mushrooms, maitake, and shiitake contain meaningful amounts. Common button mushrooms have less. For the full species comparison, the Singapore population data that underlies much of the human ergothioneine-aging research comes from a population with relatively high mushroom consumption; researchers at the National University of Singapore, including Cheah and Halliwell, have cited this as a possible factor in regional ergothioneine levels and their relationship to cognitive outcomes. For the Singapore mushroom consumption data in a cognitive health context, see Mushroom Consumption and Cognitive Decline: The Singapore Diet and Aging Study.

Ergothioneine is heat-stable and survives cooking. After absorption via OCTN1 in intestinal cells, it enters the bloodstream and is distributed to tissues. Plasma levels reflect recent dietary intake; tissue levels in the lens and retina build over time. There are no established recommendations for ergothioneine intake for eye health specifically. What is established is that mushroom consumption raises plasma ergothioneine, and that the lens and retina actively import whatever is available.

This article summarizes published research for educational purposes and is not medical advice. No supplement has been shown in human trials to prevent or treat any eye condition. If you have concerns about cataracts, macular degeneration, or your eye health, consult an eye-care professional before changing your diet or starting any supplement.

The Bottom Line

Ergothioneine was identified as the lead cytoprotective antioxidant for retinal pigment epithelium protection in a 2024 antioxidant screen (Gu 2024), acting via NRF2 activation. Both the lens and the retina concentrate ergothioneine through OCTN1, its dedicated transporter, and both tissues show signs of damage when ergothioneine depletes. All current evidence is preclinical or observational; human trials for any eye indication have not been conducted.

Frequently Asked Questions

What does ergothioneine do for the eyes?

Ergothioneine concentrates in eye tissues, including the lens and the retinal pigment epithelium, via the OCTN1 transporter. It quenches singlet oxygen generated by UV light, chelates metal ions that amplify oxidative damage, and activates the NRF2 pathway that controls antioxidant gene expression. A 2024 screen in Experimental Eye Research identified L-ergothioneine as the lead cytoprotective antioxidant for RPE cell protection, acting through NRF2 activation. Cataractous human lenses also contain markedly lower ergothioneine than normal lenses, per a 1981 human tissue analysis.

Which foods are highest in ergothioneine?

Mushrooms are the primary dietary source. Porcini mushrooms (ceps) typically contain the highest concentrations, followed by oyster mushrooms, maitake, shiitake, and king oyster varieties. Common button mushrooms contain ergothioneine but at lower levels. Ergothioneine is heat-stable and survives cooking. Animal products and most plant foods contain negligible amounts; the compound is synthesized by fungi and bacteria, making mushrooms the practical human source.

Is ergothioneine good for macular degeneration?

The preclinical evidence is encouraging but not yet tested in humans. A 2024 study in Experimental Eye Research identified ergothioneine as the lead cytoprotective antioxidant for retinal pigment epithelium cells, the cells whose death drives AMD, acting via NRF2 activation. A 2023 study found ergothioneine reduced amyloid beta deposits in the neuroretina of mice. A 2024 study found an ergothioneine-rich mushroom extract reduced cellular senescence in a neuronal model, a process also implicated in AMD. No human clinical trial has tested ergothioneine for AMD.

Can ergothioneine prevent cataracts?

Cataracts are associated with lower ergothioneine in lens tissue; cataractous human lenses contain markedly less than normal lenses (Shukla 1981), and the lens uses OCTN1 transporters to actively import ergothioneine because UV light generates singlet oxygen that ergothioneine specifically quenches. However, no human trial has tested whether ergothioneine supplementation reduces cataract risk. The evidence is observational (human tissue data) and mechanistic (UV protection pathways). It supports plausibility but not proven prevention.

What is the best antioxidant for eye health?

For retinal pigment epithelium protection specifically, Gu et al.'s 2024 antioxidant screen identified L-ergothioneine as the lead cytoprotective compound, acting via NRF2 pathway activation. For broader eye health, the evidence landscape includes lutein and zeaxanthin (with RCT data for AMD progression), vitamin C (with observational data for cataracts), and ergothioneine (with preclinical and observational data but no human trials yet). Ergothioneine has a strong, well-characterized mechanism for RPE-specific protection; lutein and zeaxanthin have the strongest clinical trial backing overall.

Sources & References

1. 1RTHM-01896·Gu, Sijie et al. (2024). “Screening and evaluation of antioxidants for retinal pigment epithelial cell protection: L-ergothioneine as a novel therapeutic candidate through NRF2 activation..” Experimental eye research.Study breakdown →PubMed →↩
2. 2RTHM-00655·Smith, Einar et al. (2020). “Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease..” Heart (British Cardiac Society).Study breakdown →PubMed →↩
3. 3RTHM-00154·Gründemann, Dirk et al. (2005). “Discovery of the ergothioneine transporter..” Proceedings of the National Academy of Sciences of the United States of America.Study breakdown →PubMed →↩
4. 4RTHM-01527·Gründemann, Dirk et al. (2022). “The ergothioneine transporter (ETT): substrates and locations, an inventory..” FEBS letters.Study breakdown →PubMed →↩
5. 5RTHM-00936·Ames, Bruce N (2018). “Prolonging healthy aging: Longevity vitamins and proteins..” Proceedings of the National Academy of Sciences of the United States of America.Study breakdown →PubMed →↩
6. 6RTHM-00004·Shukla, Y et al. (1981). “Ergothioneine content in normal and senile human cataractous lenses..” The Indian journal of medical research.Study breakdown →PubMed →↩
7. 7RTHM-00678·Cheah, Irwin K et al. (2021). “Ergothioneine, recent developments..” Redox biology.Study breakdown →PubMed →↩
8. 8RTHM-01933·Li, Yongchao et al. (2024). “Ergothioneine Protects Against UV-Induced Oxidative Stress Through the PI3K/AKT/Nrf2 Signaling Pathway..” Clinical.Study breakdown →PubMed →↩
9. 9RTHM-01819·Wijesinghe, Printha et al. (2023). “Ergothioneine, a dietary antioxidant improves amyloid beta clearance in the neuroretina of a mouse model of Alzheimer's disease..” Frontiers in neuroscience.Study breakdown →PubMed →↩
10. 10RTHM-01850·Apparoo, Yasaaswini et al. (2024). “Potential role of ergothioneine rich mushroom as anti-aging candidate through elimination of neuronal senescent cells..” Brain research.Study breakdown →PubMed →↩
11. 11RTHM-00420·Cheah, Irwin K et al. (2016). “Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration?.” Biochemical and biophysical research communications.Study breakdown →PubMed →↩
12. 12RTHM-00884·Katsube, Makoto et al. (2024). “Ergothioneine promotes longevity and healthy aging in male mice..” GeroScience.Study breakdown →PubMed →↩